Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study
In patients with DM, DPP-4i at ≤90, 91-180, 181-300 and >300 cDDD was linked to an increased risk of DR over the 5-year follow-up. Sitagliptin at cDDD 181-300 was associated with the greatest DR risk. The potential for DPP-4i to accelerate DR progression should be considered.
Authors
- Yu-Ching Li
- Kuan‐Wen Su (ORCID: https://orcid.org/0000-0001-8841-0108)
- Yih Yang
- Shuo‐Yan Gau (ORCID: https://orcid.org/0000-0001-8897-5635)
- Yu‐Hsiang Kuan (ORCID: https://orcid.org/0000-0002-8991-6394)
- Chien-Ying Lee
- Kuang‐Hua Huang (ORCID: https://orcid.org/0000-0003-4351-6202)
- Tung‐Han Tsai
Institutions
- National Taiwan University (TW)
- China Medical University (TW)
- E-Da Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Chung Shan Medical University (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fphar.2025.1518545
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- China Medical University Hospital
- China Medical University
- China Medical University, Taiwan
- Health and Welfare Data Science Center
- National Science and Technology Council